CurrentEndo — Osteoporosis, bone & mineral

Association between cognitive trajectories and subsequent hip fracture risk: a multinational prospective cohort study

2026-11-13T22:45:40.907Z

Cohort study · Osteoporos Int, 2026.

Physical and psychosocial morbidity in pregnancy and lactation-associated osteoporosis: a comprehensive mixed-methods study

2026-11-13T22:45:40.907Z

Case-control study · Osteoporos Int, 2026.

Juvenile Paget’s disease in two Chinese pedigrees carrying distinct novel homozygous TNFRSF11B variants: clinical manifestations, management, and follow-up

2026-11-13T17:46:43.542Z

Cohort study · Osteoporos Int, 2026.

Reading Hormones Through The Failing Kidney: Pitfalls in Endocrine Test Interpretation in Chronic Kidney Disease

2026-11-13T17:46:43.542Z

Research article · Endocr Pract, 2026.

Sedative-hypnotic use and its association with osteoporosis and fractures: a national analysis, 1999–2020

2026-11-13T17:46:43.542Z

Cross-sectional study · Osteoporos Int, 2026.

Opportunistic Osteoporosis Screening Using CT-Derived Volumetric Bone Mineral Density Reference Curves

2026-11-13T17:00:16.153Z

Cohort study · J Bone Miner Res, 2026.

Bisphosphonates vs Denosumab After Low-Trauma Fractures

2026-11-13T15:47:59.646Z

Cohort study · JAMA Netw Open, 2026.

Impact of Prior Bisphosphonates Exposure on the Efficacy of Denosumab in Patients with Osteoporosis: A Prospective Cohort Study

2026-11-13T15:47:59.646Z

Cohort study · Endocr Pract, 2026.

Artificial Neural Network Modeling to Predict Neonatal Metabolic Bone Disease in the Prenatal and Postnatal Periods

2026-11-13T11:00:06.281Z

Diagnostic or prognostic study · JAMA Netw Open, 2023. Prediction of MBD (AUC): Model 1: AUC 0.981 (95% CI, 0.970-0.992) · Model 2: AUC 0.647 (95% CI, 0.571-0.723) · Model 3: AUC 0.808 (95% CI, 0.726-0.891) · Model 4: AUC 0.850 (95% CI, 0.785-0.915) · Model 5: AUC 0.977 (95% CI, 0.966-0.988)

3′ Untranslated Region Structural Elements in CYP24A1 Are Associated With Infantile Hypercalcemia Type 1

2026-11-13T10:57:18.358Z

Mechanistic study · J Bone Miner Res, 2023. Molecular mechanisms of apparent HCINF1 without CYP24A1 coding mutation: Patients with profiles characteristic of altered CYP24A1 function but no protein-coding CYP24A1 mutations 6

Contributions of Clinical and Technical Factors to Longitudinal Change in Trabecular Bone Score and Bone Density: A Registry-Based Individual-Level Analysis

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2023. Change exceeding the LSC: Lumbar spine TBS: change exceeding LSC (9.3% increase, 13.8% decrease) 23.0%

Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend

2026-11-13T10:57:18.358Z

Secondary analysis · J Bone Miner Res, 2023. Cumulative TBSth increase, 43 months (18 months + 2 years alendronate): Abaloparatide/alendronate 4.4% · Placebo/alendronate 1.7%

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial

2026-11-13T10:57:18.358Z

Randomized controlled trial · J Bone Miner Res, 2022. Composite primary efficacy endpoint met, week 26: TransCon PTH 48 (79%) · Placebo 1 (5%)

Expected Benefits and Budget Impact From a Microsimulation Model Support the Prioritization and Implementation of Fracture Liaison Services

2026-11-13T10:57:18.358Z

Research article · J Bone Miner Res, 2023. Health outcomes, resource use and costs of FLSs vs current practice, 5 years: Reduction in subsequent fractures 13,149

Impact of Stroke History on the Risk of Recurrent Hip Fracture or Major Osteoporotic Fractures among Patients with Incident Hip Fracture: A Nationwide Cohort Study

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2022. Recurrent hip fracture, cumulative incidence, 1 year: Stroke history 4.6% (95% CI 3.9-5.4) · No stroke history 4.3% (95% CI 4.1-4.5)

Increased Advanced Glycation Endproducts, Stiffness, and Hardness in Iliac Crest Bone From Postmenopausal Women With Type 2 Diabetes Mellitus on Insulin

2026-11-13T10:57:18.358Z

Cross-sectional study · J Bone Miner Res, 2022. T2DM vs IGT: difference in cortical pentosidine +24%; p = 0.087

Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial

2026-11-13T10:57:18.358Z

Randomized controlled trial · J Bone Miner Res, 2023. 25(OH)D levels, month 4: Group A1 26.8 ± 8.5 ng/mL · Group B 23.1 ± 5.4 ng/mL

Longitudinal Change in Bone Density, Geometry, and Estimated Bone Strength in Older Men and Women From The Gambia: Findings From the Gambian Bone and Muscle Aging Study (GamBAS)

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2022. Annualized bone change, 1.7 years: Bone loss observed at all sites

Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2023. Risk stratification by FRAX in men with prostate cancer (HR per SD increase in FRAX score): MOF, FRAX with BMD: HR 1.91 (95% CI 1.48-2.45)

Positive Effect of Parathyroidectomy Compared to Observation on BMD in a Randomized Controlled Trial of Mild Primary Hyperparathyroidism

2026-11-13T10:57:18.358Z

Randomized controlled trial · J Bone Miner Res, 2023. BMD (DXA), treatment effect, 10 years — PTX vs OBS; p < 0.001; significant treatment effect for all compartments, most explicit for lumbar spine (LS) and femoral neck (FN)

PPI-Induced Changes in Plasma Metabolite Levels Influence Total Hip Bone Mineral Density in a UK Cohort

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2022. bone mineral density (BMD): PPI use is associated with decreased lumbar spine and total hip BMD

Reduced Peak Bone Mass in Young Adults With Low Motor Competence

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2023. BMD at load-bearing bone sites, 20 years: LMC associated with decrease in BMD at all load-bearing bone sites 1.8% to 2.6%

Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT

2026-11-13T10:57:18.358Z

Research article · J Bone Miner Res, 2022. Percentage change in HR-pQCT parameters: After teriparatide: tibial trabecular number 3.3%, p = 0.01

The Clinical and Skeletal Effects of Long-Term Therapy of Hypoparathyroidism With rhPTH(1-84)

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2023. Tibia cortical volumetric BMD (vBMD) change from baseline (high-resolution-peripheral quantitative computed tomography (HRpQCT)), years 5, 8 and 12: Year 5 -20.0% ± 1.5%

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension

2026-11-13T10:57:18.358Z

Randomized controlled trial · J Bone Miner Res, 2022. Peripheral volumetric BMD, microarchitecture and strength after ZOL, 27 months post-ZOL: Total and cortical BMD gradually decreased over 27 months; values similar to baseline at radius but still significantly above baseline at tibia

The Impact of Human Immunodeficiency Virus and Menopause on Bone Mineral Density: A Longitudinal Study of Urban-Dwelling South African Women

2026-11-13T10:57:18.358Z

Cohort study · J Bone Miner Res, 2023. Total body BMD change, 5-year follow-up — HIV vs Without HIV: mean difference -0.013 g/cm2 (95% CI -0.026, -0.001); p = 0.040; greater TB BMD loss with HIV

Trabecular Bone Score (TBS) Varies with Correction for Tissue Thickness Versus Body Mass Index: Implications When Using Pediatric Reference Norms

2026-11-13T10:57:18.358Z

Cross-sectional study · J Bone Miner Res, 2023. TBS value — TBSBMI vs TBSTH: mean difference 0.06; p < 0.0001; systematically higher with TBSBMI

Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women

2026-11-13T10:56:17.867Z

Randomized controlled trial · Osteoporos Int, 2022. PK bioequivalence (Cmax, AUC0-t, AUC0-∞): 90% CIs of geometric mean ratios (test:reference) of Cmax, AUC0-t and AUC0-∞ within 80.00%–125.00%: PK equivalence of INTG-8 to EU- and US-teriparatide for all primary endpoints

Comparison of various treatment modalities for the management of bone marrow edema syndrome/transient osteoporosis in men and non-pregnant women: a systematic review

2026-11-13T10:56:17.867Z

Meta-analysis · Osteoporos Int, 2022. Pain resolution: <1 month: bisphosphonates more efficient than CD

Discontinuation of denosumab in men with prostate cancer

2026-11-13T10:56:17.867Z

Cohort study · Osteoporos Int, 2022. Change in lumbar spine BMD, between first and second DXA: No zoledronate - 4.9 ± 4.2 %

DXA-based bone strain index in normocalcemic primary hyperparathyroidism

2026-11-13T10:56:17.867Z

Case-control study · Osteoporos Int, 2023. BSI — NHPT vs PHPT: FN-BSI; p = 0.031; FN-BSI 1.52 ± 0.31 vs 1.72 ± 0.42; lower in NHPT

Effect of pulmonary function on bone mineral density in the United States: results from the NHANES 2007–2010 study

2026-11-13T10:56:17.867Z

Cross-sectional study · Osteoporos Int, 2023. FEV1 (% predicted) and femur BMD: Positive correlation, adjusted for race, age, alcohol, body mass index (BMI), height, poor income ratio (PIR), total protein, serum calcium, uric acid, cholesterol, phosphorus, blood urea nitrogen β 0.032 (95% CI 0.010-0.054, P = 0.004)

Effect of soluble corn fibre and calcium supplementation on bone mineral content and bone mineral density in preadolescent Malaysian children—a double-blind randomised controlled trial (PREBONE-Kids Study)

2026-11-13T10:56:17.867Z

Randomized controlled trial · Osteoporos Int, 2023. 12 months: Changes in TBBMD and TBBMC not significantly different among groups at 12 months

Effectiveness of whole-body vibration on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials

2026-11-13T10:56:17.867Z

Meta-analysis · Osteoporos Int, 2022. aBMD, WBV vs control: Significant effects on aBMD in primary analysis (lumbar spine and trochanter)

Exercise training and bone mineral density in postmenopausal women: an updated systematic review and meta-analysis of intervention studies with emphasis on potential moderators

2026-11-13T10:56:17.867Z

Meta-analysis · Osteoporos Int, 2023. BMD change — Exercise vs Control: SMD, LS-BMD 0.29 (95% CI 0.16-0.42); I2 = 68%

High rate of abdominal aortic calcification in COPD patients and its relationship with musculoskeletal fragility

2026-11-13T10:56:17.867Z

Cross-sectional study · Osteoporos Int, 2022. Abdominal aortic calcification: AAC ≥ 1 Two-thirds of the participants

Lipopolysaccharide-binding protein and bone health: data from a population-based sample of men

2026-11-13T10:56:17.867Z

Cross-sectional study · Osteoporos Int, 2022. Association of ln-LBP with bone measures: Serum LBP range 1.07-208.53 ng/mL

Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury

2026-11-13T10:56:17.867Z

Randomized controlled trial · Osteoporos Int, 2023. Percent decrease in mean bone mineral density (BMD), hip and knee regions, 18 to 30 months: Percent decreases in mean BMD at all hip and knee regions similar in denosumab and placebo

Opportunistic measures of bone mineral density at multiple skeletal sites during whole-body CT in polytrauma patients

2026-11-13T10:56:17.867Z

Cross-sectional study · Osteoporos Int, 2023. BMD across skeletal sites: Highest BMD in cranial bones 629 Hounsfield units (HU)

Prevalence of low bone mineral density (T-score ≤ − 2.5) in the whole spectrum of chronic kidney disease: a systematic review and meta-analysis

2026-11-13T10:56:17.867Z

Meta-analysis · Osteoporos Int, 2022. Pooled global prevalence of LBMD in CKD: Pooled global prevalence of LBMD in CKD 24.5% (95% CI, 21.3 - 27.8%)

Pubertal increment in insulin resistance is negatively related to lumbar bone mineral density in 18-year-old males

2026-11-13T10:56:17.867Z

Cohort study · Osteoporos Int, 2022. Pubertal increment in HOMA-IR as predictor of lumbar spine BMD, adjusted for baseline bone indices and body composition, age 18 years: Lumbar spine bone mineral areal density, β (p = 0.005) - 0.202

Metabolically favorable adiposity and bone mineral density: a Mendelian randomization analysis

2026-11-13T10:47:54.884Z

Research article · Obesity (Silver Spring), 2022. Association of genetically predicted MFA with areal bone mineral density (aBMD): MFA vs whole-body aBMD, β (p = 0.0002) -0.053

Site-Specific Fracture Incidence Rates Among Patients With Type 1 Diabetes, Type 2 Diabetes, or Without Diabetes in Denmark (1997–2017)

2026-11-13T10:12:25.062Z

Cohort study · Diabetes Care, 2023. Fracture IRs by site, 1997-2017: Except for foot fractures, fracture IRs higher in T1D or T2D vs without diabetes

Novel Calcium-Sensing Receptor (CASR) Mutation in a Family with Autosomal Dominant Hypocalcemia Type 1 (ADH1): Genetic Study over Three Generations and Clinical Characteristics

2026-11-13T10:10:38.237Z

Research article · Horm Res Paediatr, 2023. Sensitivity of CASR to activation by EC50: p.Ile139Thr 0.88 ± 0.02 mM · Wild type 1.1 ± 0.23 mM

A Parathyroid Hormone–Guided Calcium and Calcitriol Supplementation Protocol Reduces Hypocalcemia-Related Readmissions Following Total Thyroidectomy

2026-11-13T10:04:31.875Z

Cohort study · Endocr Pract, 2023. Postoperative hypocalcemia: Protocol 10.3% · Preprotocol 20.9%

Age-Related Factors Associated With The Risk of Hip Fracture

2026-11-13T10:04:31.875Z

Cohort study · Endocr Pract, 2023. Age-related factors associated with hip fracture risk: Microvascular disease of kidneys (albuminuria and/or elevated urine albumin-to-creatinine ratio) and brain (abnormal white matter disease on brain MRI) significantly associated with hip fracture risk

Albuminuria, Disease Duration, and Glycated Hemoglobin Are Related With Bone Mineral Density in Type 1 Diabetes: A Cross-sectional Study

2026-11-13T10:04:31.875Z

Cross-sectional study · Endocr Pract, 2023. Factors associated with BMD (adjusted linear models): Higher albuminuria associated with lower femoral neck and total hip BMD P < .01

Bone Fragility in Hereditary Connective Tissue Disorders: A Systematic Review and Meta-Analysis

2026-11-13T10:04:31.875Z

Meta-analysis · Endocr Pract, 2023. Pooled prevalence of fracture: EDS 44% (95% CI 25% to 65%); I2 88% · MFS 17% (95% CI 11% to 26%); I2 68% · LDS 69% (95% CI 47% to 85%); I2 83%

Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders

2026-11-13T10:04:31.875Z

Diagnostic or prognostic study · Endocr Pract, 2023. Elevated iFGF23 vs healthy controls: TIO 90% · XLH 84%

Parathyroid Cystic Adenoma: A Systematic Review and Meta-Analysis

2026-11-13T10:04:31.875Z

Meta-analysis · Endocr Pract, 2022. PCA detection rate: US 86% · US-guided FNA 100% · 4D-CT 100% · MRI 100% · (99m)Tc-SPECT 61%